After receiving omalizumab, which physical assessment finding indicates that a pediatric client might be experiencing a life-threatening side effect?

Omalizumab is a monoclonal antibody used to treat moderate to severe asthma and allergic conditions by inhibiting IgE binding, thus reducing allergic inflammation. One of the life-threatening side effects associated with omalizumab is anaphylaxis, which can manifest through severe allergic reactions.

Swelling of the tongue, or glossitis, is a critical sign of an anaphylactic reaction. It can lead to airway obstruction, presenting a serious risk to the patient’s breathing and overall safety. The swelling can restrict airflow, making it a medical emergency requiring immediate attention. Recognizing this symptom is vital for prompt intervention.

In contrast, increased heart rate, rash on the stomach, and persistent coughing, while concerning, are not as dire a sign of an immediate and life-threatening reaction as swelling of the tongue. They may indicate other issues or less severe reactions that do not require urgent intervention. Therefore, swelling of the tongue is a clear and serious indicator of a potential life-threatening side effect post-omalizumab administration.